AIDX — what changed in the latest 10-Q
A section-by-section comparison of AIDX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +28 | −25 | ~19 | 18 |
| Controls & procedures | Text added/removed | 0 | 0 | ~4 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Other information | Text added/removed | 0 | 0 | ~2 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
On July 16, 2026, we entered into a standstill agreement with Streeterville Capital, LLC, or Streeterville, pursuant to which Streeterville agreed that, for the period beginning on the date of the standstill agreement and ending on the date that is one hundred twenty (120) days thereafter, it would …
The following table sets forth key components of our results of operations during the three months ended June 30, 2026 and 2025, both in dollars and as a percentage of our revenues.
Revenues. We generated revenues from sales of OneTest, BioCheck and from our CLIAx during the three months ended June 30, 2026 and 2025. Our total revenues increased by $195,511, or 36.54%, to $730,571 for three months ended June 30, 2026 from $535,060 for the three months ended June 30, 2025. Such …
Revenues from sales of OneTest increased by $222,773, or 47.08%, to $695,947 for the three months ended June 30, 2026 from $473,174 for the three months ended June 30, 2025. This increase was primarily due to an expansion of Maryland fire departments seeking the Company’s OneTest™ Multi-Cancer Early…
Revenues from sales of BioCheck decreased by $6,245, or 15.28%, to $34,624 for the three months ended June 30, 2026 from $40,869 for the three months ended June 30, 2025. This decrease was primarily due to continued years-long decline since patents covering that product expired in 2021 and more dire…
Text removed vs the prior filing · source: 10-Q · 2026-05-20
On April 10, 2026, all principal and accrued interest due under the secured convertible promissory notes described below was exchanged for 583 shares of series E convertible preferred stock in accordance with the terms of the secured convertible promissory notes.
On April 23, 2026, we entered into a global amendment with Streeterville Capital, LLC, or Streeterville, pursuant to which the exercise price of the warrants issued to it on November 17, 2025, February 9, 2026 and February 16, 2026 described below was reduced to $2.25 per share (subject to standard …
Comparison of the Three Months Ended March 31, 2026 and 2025
The following table sets forth key components of our results of operations during the three months ended March 31, 2026 and 2025, both in dollars and as a percentage of our revenues.
Revenues. We generated revenues from sales of OneTest, BioCheck and from our CLIAx during the three months ended March 31, 2026 and 2025. Our total revenues decreased by $200,445, or 36.19%, to $353,375 for three months ended March 31, 2026 from $553,820 for the three months ended March 31, 2025. Su…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice